Using phosphazide in regimes of ART in patients co‐infected with HIV and HCV receiving treatment of hepatitis

Purpose Comparing of the efficacy and safety of treatment of chronic hepatitis C PegIFN and RBV in HIV‐infected patients receiving HAART with phosphazide (PhAZT) or abacavir (ABC). Methods 81 co‐infected with HIV/HCV patients with ART>3 months, treated by PegIFN and RBV (1000–1200 mg/day by weigh...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the International AIDS Society 2012-11, Vol.15 (S4), p.1-1
Main Authors: Kravchenko, A, Kanestri, V, Kuimova, U, Gankina, N, Serebrovskaya, L
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
AIDS
Antiretroviral drugs
Genotype & phenotype
Hepatitis
Hepatitis C
HIV
Human immunodeficiency virus
Sexually transmitted diseases
STD
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Comparing of the efficacy and safety of treatment of chronic hepatitis C PegIFN and RBV in HIV‐infected patients receiving HAART with phosphazide (PhAZT) or abacavir (ABC). Methods 81 co‐infected with HIV/HCV patients with ART>3 months, treated by PegIFN and RBV (1000–1200 mg/day by weight) during 24–48 weeks. 50 patients (group 1) received PhAZT+3TC+EFV or PIs, and 31 patients (group 2) ‐ABC+3TC+EFV or PIs. Patients in both groups did not differ by sex, age, stage of HIV infection, body mass index, HCV genotype, HCV RNA levels, the degree of hepatic fibrosis. Results Virologic response EOT in 1st group was 74% (genotype 1–56%, genotype 3–92%), in 2nd group‐75.9% (genotype 1–61.5%; genotype 3–87.5%). Sustained virological response (SVR) in 1st group was 62% (genotype 1–44%, genotype 3–80%), and in 2nd group −53.3% (genotype 1–46.7%, genotype 3–60%). Relapse of HCV replication within 24 wks after therapy was observed in 12% of pts with 1st group and 22.6%‐2nd group (p
ISSN:1758-2652
1758-2652
DOI:10.7448/IAS.15.6.18430